PDCD1 and neoplasm: PD-1/PD-L1 inhibitors liberate antitumor immunity by interrupting the inhibitory axis between T-cell PD-1 and PD-L1/PD-L2 expressed on SCLC tumor cells and on tumor-infiltrating macrophages or dendritic cells (72).